That still seems dodgy. Patients didn't get a response from std care... well, that is the whole point of bringing a new product to market. If std care worked, what is even the point of the RCE pixie gel? How do they know it's not RCE + std care that's actually having the effect? Isn't that important to know before heading into an expensive Phase 3?
What you're talking about with control arm patients having access to R327 after the trial is an open label extension. It's pretty standard now in P3s and it's kind of pathetic that they are bragging about an OLE in their imaginary future P3.
It's also weird that there is still no FDA IND yet, as far as I know? Maybe I missed it, but surely an IND would be expected at this stage?
IV / sepsis seems to be abandoned now, all hopes pinned on making a better Dettol.
And still no Indonesian trial started! They said it was starting mid-December; two months late before even starting!
Wow. Recce is still my favourite form of entertainment. Nearly 8 years of this so far, and I reckon 2 more to go.
RCE Price at posting:
45.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)